| Oct 2 |
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
|
| Oct 2 |
J&J prostate cancer therapy outperforms in real-world study
|
| Oct 2 |
ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
|
| Oct 2 |
J&J to invest over $2B to build new North Carolina plant
|
| Oct 1 |
U.S. port strike expected to have limited impact on healthcare supply chain: HHS
|
| Oct 1 |
55-Year-Old Who Reached $3,900 Per Month Income In Just 5 Years Shares Portfolio: Top 9 Stocks And ETFs
|
| Oct 1 |
J&J to invest over $2 billion for new manufacturing facility in North Carolina
|
| Oct 1 |
Johnson & Johnson (NYSE:JNJ) is a favorite amongst institutional investors who own 73%
|
| Oct 1 |
Johnson & Johnson launches TECNIS Odyssey intraocular lens in US
|
| Oct 1 |
J&J drops 340B rebate plan following government pressure
|
